Abstract
Our two meta-analyses show that antilymphocyte antibody induction therapy extends allograft survival when compared to induction therapy with cyclosporine, azathioprine, and prednisone with the majority of the benefit seen during the first 2 years after transplant. The benefit of induction therapy with respect to allograft survival is particularly important among patients with pretransplant panel reactive antibodies greater than 20%. Although our understanding of the role of antilymphocyte antibody induction therapy continues to evolve, these two meta-analyses provide evidence for its use in clinical renal transplantation.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
